BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/25/2014 7:26:00 PM | Browse: 633 | Download: 375
Publication Name World Journal of Gastroenterology
Manuscript ID 6460
Country/Territory United Kingdom
Received
2013-10-19 10:33
Peer-Review Started
2013-10-22 08:54
To Make the First Decision
2013-12-26 11:38
Return for Revision
2013-12-26 18:31
Revised
2014-01-15 18:16
Second Decision
2014-04-03 10:03
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-04-03 11:26
Articles in Press
2014-05-23 10:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-06-16 15:36
Publish the Manuscript Online
2014-07-14 17:39
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Research and Experimental Medicine
Manuscript Type Topic Highlights
Article Title Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation
Manuscript Source Invited Manuscript
All Author List Stacey J Coleman, Jennifer Watt, Prabhu Arumugam, Leonardo Solaini, Elisabeta Carapuca, Mohammed Ghallab, Richard P Grose and Hemant M Kocher
Funding Agency and Grant Number
Corresponding author Hemant M Kocher, MS, MD, FRCS, Centre for Tumour Biology, Barts Cancer Institute - a CR-UK Centre of Excellence, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom. h.kocher@qmul.ac.uk
Key Words 3D organotypic model; Pancreatic cancer; Pancreatic stellate cell; Stroma; Preclinical models
Core Tip Pancreatic cancer carries a terrible prognosis, as the fourth most common cause of cancer death in the Western world. One of the reasons no effective treatment has been developed in the past decade may in part, be explained by the influences exerted by the tumour microenvironment. The tumour stroma cross-talk in pancreatic cancer can influence chemotherapy delivery and response rate. Organotypic models of pancreatic cancer allow new therapies that can target the cancer, the stromal compartment or both to be tested in a model that mirrors the in vivo situation and can help improve patient prognosis.
Publish Date 2014-07-14 17:39
Citation Coleman SJ, Watt J, Arumugam P, Solaini L, Carapuca E, Ghallab M, Grose RP, Kocher HM. Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluation. World J Gastroenterol 2014; 20(26): 8471-8481
Url http://www.wjgnet.com/1007-9327/full/v20/i26/8471.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i26.8471
Full Article (PDF) WJG-20-8471.pdf
Full Article (Word) WJG-20-8471.doc
Manuscript File 6460-Review.doc
Answering Reviewers 6460-Answering reviewers.pdf
Copyright License Agreement 6460-Copyright assignment.pdf
Peer-review Report 6460-Peer review(s).pdf
Scientific Editor Work List 6460-Scientific editor work list.doc